Biodefense Stocks News: Aethlon Medical (NASDAQ: $AEMD) CEO Note: Bill
Gates on the Threat of Bioterrorism
SAN DIEGO, CA (Investorideas Newswire) Aethlon
Medical, Inc. (Nasdaq: AEMD), recently released the following note authored by
its Chairman and CEO, Jim Joyce.
In a chilling address at the Munich Security
Conference last Saturday, Bill Gates warned world leaders that a genetically
engineered virus could kill more people than nuclear weapons. Mr. Gates
expressed his concern, which is also supported by U.S. and U.K. intelligence
agencies, that scientific terrorists have access to the necessary tools to
design biological viruses to be weapons that could kill tens of millions of
people. He also concluded that in the face of such knowledge, governments
around the world remain complacent and are neither prepared nor equipped to
respond to these threats.
If you are a shareholder of Aethlon Medical, you may
recognize the concerns of Mr. Gates to be eerily similar to our own. As a
recent example, I encourage you to review the bioterror related article that we
published last year on the 21st of December.
For those dedicated to the advancement of bioterror
treatment solutions, Mr. Gates is a welcome and respected voice with the
visibility, influence and knowledge to recognize that therapeutic innovation
will be required to counter deadly viruses created by man.
If bioterrorists were to release such a virus, I am
sincerely unaware of a clinical-stage candidate beyond our Hemopurifier® that
could be deployed as a post-exposure treatment countermeasure.
The void in bioterrorism treatment countermeasures is
driven by a historic emphasis to align a disease-specific drug or vaccine which
only targets one specific pathogen threat. Such strategies have had limited
success against the breadth of threats that are known to be infectious to man
and cannot be considered as a strategy to treat unknown viruses created by man.
In reality, only a fraction of the 300+ viruses known
to be infectious to man are addressed with an FDA-cleared drug or
vaccine. Since 2001, our government has spent an estimated $80 billion on
biodefense initiatives, yet just one of 13 viruses classified as "Category
A" are addressed with an approved therapy. "Category A"
pathogens are those biological threats that pose the highest risk to national
security and public health. In addition, these types of viral pathogens
maintain the potential to be genetically engineered to be used as weapons that
are even more deadly and resistant than those viruses that are naturally
occurring.
Our Hemopurifier® is a first-in-class medical
technology currently being advanced in FDA approved studies. In previous
studies, our technology has demonstrated the ability to capture a wide range of
bioterror related, pandemic, chronic and latent infectious viral pathogens.
We believe the Hemopurifier® can fulfill the
broad-spectrum medical countermeasure objective of the U.S. Department of
Health and Human Services (HHS) Public Health Emergency Medical Countermeasure
Enterprise (PHEMCE). This initiative is directed toward bioterror,
pandemic threats and other pathogens that are not well addressed with
traditional drug or vaccine therapies.
A little more than a decade ago, we were invited to
attend an international scientific symposium hosted by the National Center for
Biodefense. At the time, our Hemopurifier® was still a development-stage
vision. Regardless, the keynote speaker, who formerly led the Soviet Union's
biological weapons program, emphasized our approach to be the only way to
counter the breadth of viruses that could emerge naturally through mother
nature or be created by man as agents of bioterror.
We never forgot that statement.
Read this release in full at http://www.investorideas.com/news/2017/biotech/03022AEMD.asp
About the Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical
technology currently being advanced in FDA approved studies as a broad-spectrum
treatment countermeasure against infectious viral pathogens. Named a
"Top 25 Invention" and one of the "Eleven Most Remarkable
Advances in Healthcare," by TIME Magazine, the Hemopurifier® has
previously been administered to individuals infected with Ebola virus,
Hepatitis C virus and the Human Immunodeficiency virus, which leads to HIV AIDS.
Beyond human treatment experiences, pre-clinical
Hemopurifier® studies have validated the capture of Chikungunya, Dengue, Middle
East Respiratory Syndrome Coronavirus, West Nile and Zika virus, as well as
Vaccinia and Monkey pox, which serve as models for human Smallpox
infection. Specific to pandemic influenza threats, Aethlon has validated
the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918
influenza virus, which represents a model for the strain of influenza that
killed an estimated 50 million victims in 1918 and 1919.
The Hemopurifier has also been demonstrated to capture
Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1
(HSV1), which are latent viruses often associated with increased mortality in
immune-suppressed sepsis patients. These pathogens also contribute to
organ rejection in transplant patients. To validate treatment
performance, the Hemopurifier is supported by the HP Virus Capture Assay, which
quantifies the number of viruses captured within the Hemopurifier and no longer
circulating in the patient.
About Aethlon Medical
Aethlon Medical (AEMD) is a leading developer of
immunotherapeutic technologies to combat infectious disease and cancer.
To augment the body's natural immune defenses, the Aethlon Hemopurifier®
eliminates life-threatening disease targets that are often shielded from the
immune system and not well addressed by traditional drug therapies. The
technology captures circulating viruses, bacterial toxins and cancer promoting
exosomes through affinity attachment to a unique structure that cloaks these
targets from immune detection. At present, the Hemopurifier® is being advanced
under an FDA approved clinical study. Aethlon is also the majority owner of
Exosome Sciences, Inc., a company focused on the discovery of exosomal
biomarkers to diagnose and monitor life-threatening diseases. Aethlon is
part of the Russell Microcap® Index. Additional information can be found
online at www.AethlonMedical.com or
you can connect with us on Twitter, LinkedIn, Facebook and Google+.
This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934 that involve risks and uncertainties.
Statements containing words such as "may," "believe,"
"anticipate," "expect," "intend,"
"plan," "project," "will,"
"projections," "estimate," or similar expressions
constitute forward-looking statements. Such forward-looking statements are
subject to significant risks and uncertainties and actual results may differ
materially from the results anticipated in the forward-looking statements.
Factors that may contribute to such differences include, without limitation,
the Company's ability to maintain its listing on the Nasdaq Capital Market, or
any other national securities exchange, that the Company or its subsidiary will
not be able to commercialize its products, that the FDA will not approve the
initiation or continuation of the Company's clinical programs or provide market
clearance of the Company's products, including any products relating to the
Zika or MERS-CoV viruses or relating to sepsis, the Company's ability to raise
capital when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products either
internally or through outside companies, the impact of government regulations,
patent protection on the Company's proprietary technology, the ability of the
Company to meet the milestones contemplated in its contract with DARPA, product
liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. The foregoing list of risks and
uncertainties is illustrative, but is not exhaustive. Additional factors that
could cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended March
31, 2016, and in the Company's other filings with the Securities and Exchange
Commission. Except as may be required by law, the Company does not intend, nor
does it undertake any duty, to update this information to reflect future events
or circumstances.
Contacts:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-489-7800 extension 3300
Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Contact each company directly regarding content and
press release questions. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD is a previous showcase company.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each
country.
BioDefenseStocks.com - investing ideas in biodefense
stocks
Like Biodefense Stocks? View our Biodefense Stocks
Directory
